<h4>Background</h4>Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson's disease (PD). The gene discussed is GLP1R; the disease is Parkinson disease.